Curis

CRIS

Current ValuationThe current P/E ratio is -0.04, above the reasonable range, cheaper than 0.08% of the time in the past 5 years, and the industry ranks 86/605, the industry Median -1.93.

-0.0449xP/E
Stock price$0.39Earnings per share$-8.72

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-58.77x150.60%$190.42B
MRNAUSModerna
-31.14x15.78%$98.14B
CSLLYUSCSL Limited
-25.46x--$65.67B
NTRAUSNatera
-309.79x6.09%$59.59B
RVMDUSRevolution Medicines
-23.55x61.94%$41.64B
ROIVUSRoivant Sciences
-99.84x146.69%$26.58B
BNTXUSBioNTech SE
-11.73x19.62%$22.93B
INSMUSInsmed
-23.46x75.01%$20.54B
BBIOUSBridgebio Pharma
-19.14x28.60%$13.24B
SMMTUSSummit Therapeutics
-14.75x19.79%$12.63B
MDGLUSMadrigal Pharma
-32.55x51.30%$10.58B
PCVXUSVaxcyte
-9.35x47.91%$9.95B
TWSTUSTwist Bioscience
-71.81x28.71%$9.82B
KYMRUSKymera Therapeutics
-31.26x5.24%$9.37B
IBRXUSImmunityBio
-9.23x151.32%$9.16B
CYTKUSCytokinetics
-9.78x6.85%$8.74B
ARWRUSArrowHead Pharma
-25.98x35,923.70%$8.31B
SYREUSSpyre Therapeutics
-54.56x45.60%$8.20B
ABVXUSAbivax SA
-17.53x22.99%$8.15B
IONSUSIonis Pharma
-13.02x49.51%$7.36B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.